文献速递细菌感染、耐药与抗菌药物医院感染防控

英国和爱尔兰医院获得性下呼吸道感染病原体耐药趋势:2008/09至2018/19年

Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该研究基于BSAC监测网络,收集2008/09至2018/19年间英国和爱尔兰哨点医院的医院获得性下呼吸道感染主要病原体,采用琼脂稀释法检测MIC。结果显示主要病原体耐药率未出现大幅上升,部分关键耐药组合显著下降,如MRSA占比从约40%降至10%。

要点

  • MRSA占金黄色葡萄球菌比例从约40%降至10%。
  • 碳青霉烯类、氨基糖苷类和氟喹诺酮类三重耐药鲍曼不动杆菌从约24%降至9%。
  • 大肠埃希菌和肺炎克雷伯菌的头孢菌素耐药主要由ESBL介导,未见显著下降。

核心结论

  • 2008/09至2018/19年间,医院获得性下呼吸道感染主要病原体的耐药率未出现大幅上升,部分重要病原体/耐药组合显著下降。

研究设计与样本

  • BSAC监测研究,自2008/09至2018/19年从哨点医院收集医院获得性下呼吸道感染主要病原体,采用BSAC琼脂稀释法检测MIC,并通过协同试验、解释性读取和PCR推断耐药机制。

主要发现

  • MRSA占金黄色葡萄球菌比例从约40%降至10%。
  • 自2012/13年起,碳青霉烯类、氨基糖苷类和氟喹诺酮类三重耐药的鲍曼不动杆菌(狭义)从约24%降至9%。
  • 阴沟肠杆菌和沙雷菌属中AmpC相关头孢菌素耐药下降,肠杆菌目(除肺炎克雷伯菌外)氟喹诺酮类耐药下降。
  • 铜绿假单胞菌耐药率保持较低,但高于菌血症分离株。
  • 大肠埃希菌和肺炎克雷伯菌的头孢菌素耐药主要与ESBL相关,未见显著下降;除鲍曼不动杆菌OXA-23外,碳青霉烯酶仍极罕见。

关键数值与推荐

  • 抗葡萄球菌噁唑烷酮类、替加环素、头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦和头孢托罗保持未侵蚀的活性。

临床怎么用

  • 监测数据显示医院获得性下呼吸道感染主要病原体耐药未大幅上升,部分耐药下降,但ESBL相关头孢菌素耐药持续存在,应继续加强耐药监测。

局限性

  • 不动杆菌属收集数量少,反映发病率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To survey trends in antimicrobial resistance among the pathogens of hospital-acquired lower respiratory tract infection (HA-LRTI), which causes significant mortality and morbidity, particularly among ventilated patients. METHODS: The BSAC Surveillance collected quotas of major HA-LRTI pathogens from sentinel sites from 2008/09 (October to September) to 2018/19. MIC testing was by BSAC agar dilution. Resistance mechanisms were inferred from synergy tests, interpretive reading and PCR. RESULTS: Target numbers of Staphylococcus aureus, Pseudomonas aeruginosa and Enterobacterales-dominated by Escherichia coli and Klebsiella spp.-were reliably collected. Acinetobacter spp. collections were small, reflecting low incidence. Resistance rates fell or fluctuated, with no major rises. Notable declines included: (i) a fall in the proportion of MRSA among S. aureus from c. 40% to 10%; (ii) a halving, since 2012/13, in 'triple-resistance' to carbapenems, aminoglycosides and fluoroquinolones among Acinetobacter baumannii sensu stricto, from c. 24% to 9%; (iii) reductions in AmpC-associated cephalosporin resistance among Enterobacter cloacae and Serratia isolates, and (iv) falls in fluoroquinolone resistance among Enterobacterales, except Klebsiella pneumoniae. Resistance rates in P. aeruginosa remained low, though higher than in bacteraemia. Cephalosporin resistance in E. coli and K. pneumoniae was largely ESBL associated and, unlike AmpC-associated resistance in Enterobacter and Serratia spp., did not decline notably. Except for OXA-23 in A. baumannii, carbapenemases remained extremely rare. Antistaphylococcal oxazolidinones, tigecycline, ceftolozane/tazobactam, ceftazidime/avibactam and ceftobiprole retained uneroded activity. CONCLUSIONS: From 2008/09 to 2018/19, there were no major rises in resistance among the principal agents of HA-LRTI; for several important organisms/resistance combinations there were notable declines.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Reynolds R, Morrissey I, Mushtaq S, et al. Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019. J Antimicrob Chemother. 2025. PMID: 41140272. doi:10.1093/jac/dkaf251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。